Search

Your search keyword '"Pozo‐Rosich, Patricia"' showing total 742 results
Start Over Author "Pozo‐Rosich, Patricia"
742 results on '"Pozo‐Rosich, Patricia"'

19. Migraine treatment consensus document of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment

Author

Belvís, Robert, Irimia, Pablo, González, Nuria, García-Ull, Jésica, Pozo-Rosich, Patricia, López-Bravo, Alba, Morollón, Noemí, Quintas, Sonia, Plana, Antoni, Baz, Pablo Gregorio, Tentor, Ana, Gallego Artiles, Natalia, León, Francisco Javier, Pérez Martín, Miguel, Rivera, Inés, Ramírez, Raquel, Colomina, Isabel, Lainez, José Miguel, and Pascual, Julio

Published
2024
Full Text
View/download PDF

20. Documento de consenso de la Sociedad Española de Neurología (SEN), Sociedad Española de Medicina de Familia y Comunitaria (SEMFYC), Sociedad de Medicina de Atención Primaria (SEMERGEN) y Asociación Española de Migraña y Cefalea (AEMICE) sobre el tratamiento de la migraña

Author

Belvís, Robert, Irimia, Pablo, González, Nuria, García-Ull, Jésica, Pozo-Rosich, Patricia, López-Bravo, Alba, Morollón, Noemí, Quintas, Sonia, Plana, Antoni, Baz, Pablo Gregorio, Tentor, Ana, Gallego Artiles, Natalia, León, Francisco Javier, Pérez Martín, Miguel, Rivera, Inés, Ramírez, Raquel, Colomina, Isabel, Lainez, José Miguel, and Pascual, Julio

Published
2024
Full Text
View/download PDF

22. Reply to the letter: Headaches during/after SARS‐CoV‐2 infection/vaccination can be primary and secondary as well as acute and chronic, by Finsterer J and Mehri S

Author

Mitsikostas, Dimos‐Dimtirios D., primary, Caronna, Edoardo, additional, De Tommaso, Marina, additional, Deligianni, Christina I., additional, Ekizoglu, Esme, additional, Bolay, Hayrunnisa, additional, Göbel, Carl H., additional, Kristoffersen, Espen Saxhaug, additional, Lampl, Christian, additional, Moro, Elena, additional, Pozo‐Rosich, Patricia, additional, Sellner, Johann, additional, Terwindt, Gisela, additional, and Irimia‐Sieira, Pablo, additional

Published
2024
Full Text
View/download PDF

23. Benefit-Risk Assessment Based on Number Needed to Treat and Number Needed to Harm: Atogepant vs Calcitonin Gene–Related Peptide Monoclonal Antibodies (P5-12.007)

Author

Sacco, Simona, primary, Lalla, Anjana, additional, Singh, Rashmi Halker, additional, Holle-Lee, Dagney, additional, Pozo-Rosich, Patricia, additional, Nagy, Krisztian, additional, Kelton, Kari, additional, Piron, Cristiano, additional, Gandhi, Pranav, additional, and Ailani, Jessica, additional

Published
2024
Full Text
View/download PDF

27. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure

Author

Sacco, Simona, Lampl, Christian, Amin, Faisal Mohammad, Braschinsky, Mark, Deligianni, Christina, Uludüz, Derya, Versijpt, Jan, Ducros, Anne, Gil-Gouveia, Raquel, Katsarava, Zaza, Martelletti, Paolo, Ornello, Raffaele, Raffaelli, Bianca, Boucherie, Deirdre M., Pozo-Rosich, Patricia, Sanchez-del-Rio, Margarita, Sinclair, Alexandra, Maassen van den Brink, Antoinette, and Reuter, Uwe

Published
2022
Full Text
View/download PDF

29. Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury

Author

Ashina, Håkan, Diener, Hans Christoph, Tassorelli, Cristina, Scher, Ann I., Lipton, Richard B., Pozo-Rosich, Patricia, Sinclair, Alexandra J., Chong, Catherine D., Finkel, Alan G., Ashina, Messoud, Schwedt, Todd J., Dodick, David W., Terwindt, Gisela M., Ashina, Håkan, Diener, Hans Christoph, Tassorelli, Cristina, Scher, Ann I., Lipton, Richard B., Pozo-Rosich, Patricia, Sinclair, Alexandra J., Chong, Catherine D., Finkel, Alan G., Ashina, Messoud, Schwedt, Todd J., Dodick, David W., and Terwindt, Gisela M.

Abstract

Background Persistent headache attributed to traumatic injury to the head is divided into two subtypes, one attributed to moderate or severe traumatic injury and another attributed to mild traumatic injury (i.e., concussion). The latter is much more prevalent, in part because more than 90% of cases with traumatic brain injury are classified as mild. The pathophysiology of persistent post-traumatic headache is poorly understood and the underlying mechanisms are likely multifactorial. There is currently no approved treatment specifically for persistent post-traumatic headache, and management strategies rely on medications used for migraine or tension-type headache. Therefore, high-quality trials are urgently needed to support clinical decision-making and optimize management strategies. International guidelines can facilitate appropriate trial design and ensure the acquisition of high-quality data evaluating the efficacy, tolerability, and safety of available and novel pharmacological therapies for the preventive treatment of persistent post-traumatic headache. Methods The development of this guideline was based on a literature review of available studies in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, along with a review of previously published guidelines for controlled trials of preventive treatment for episodic and chronic migraine. The identified literature was critically appraised, and due to the scarcity of scientific evidence, recommendations were primarily based on the consensus of experts in the field. Objective To provide guidelines for designing state-of-the-art controlled clinical trials aimed at evaluating the effectiveness of preventive treatments for persistent post-traumatic headache attributed to mild traumatic brain injury., BACKGROUND: Persistent headache attributed to traumatic injury to the head is divided into two subtypes, one attributed to moderate or severe traumatic injury and another attributed to mild traumatic injury (i.e., concussion). The latter is much more prevalent, in part because more than 90% of cases with traumatic brain injury are classified as mild. The pathophysiology of persistent post-traumatic headache is poorly understood and the underlying mechanisms are likely multifactorial. There is currently no approved treatment specifically for persistent post-traumatic headache, and management strategies rely on medications used for migraine or tension-type headache. Therefore, high-quality trials are urgently needed to support clinical decision-making and optimize management strategies. International guidelines can facilitate appropriate trial design and ensure the acquisition of high-quality data evaluating the efficacy, tolerability, and safety of available and novel pharmacological therapies for the preventive treatment of persistent post-traumatic headache. METHODS: The development of this guideline was based on a literature review of available studies in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, along with a review of previously published guidelines for controlled trials of preventive treatment for episodic and chronic migraine. The identified literature was critically appraised, and due to the scarcity of scientific evidence, recommendations were primarily based on the consensus of experts in the field. OBJECTIVE: To provide guidelines for designing state-of-the-art controlled clinical trials aimed at evaluating the effectiveness of preventive treatments for persistent post-traumatic headache attributed to mild traumatic brain injury.

Published
2024

30. Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type:Post Hoc Analyses of the DELIVER Study

Author

Pozo-Rosich, Patricia, Ashina, Messoud, Tepper, Stewart J., Jensen, Sidsel, Boserup, Line Pickering, Josiassen, Mette Krog, Sperling, Bjørn, Pozo-Rosich, Patricia, Ashina, Messoud, Tepper, Stewart J., Jensen, Sidsel, Boserup, Line Pickering, Josiassen, Mette Krog, and Sperling, Bjørn

Abstract

Introduction In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2–4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across the 24-week placebo-controlled period of the DELIVER study in subgroups defined by prior treatment failure type. Methods DELIVER (NCT04418765) randomized adults with migraine to eptinezumab 100 mg, 300 mg, or placebo, administered intravenously every 12 weeks. Changes from baseline in MMDs and percentages of patients with ≥ 50% reduction from baseline in MMDs (≥ 50% migraine responder rates [MRRs]) were summarized in subgroups of patients defined by prior treatment failure type. Subgroups were not mutually exclusive and included patients for whom topiramate, beta blockers (metoprolol, propranolol), amitriptyline, and/or flunarizine had failed. Results Across Weeks 1–12 in all subgroups, patients treated with eptinezumab experienced greater reductions from baseline in MMDs than those receiving placebo (reductions ranged from 4.5–5.5 vs 1.6–2.4, respectively), with larger reductions over Weeks 13–24. Similarly, ≥ 50% MRRs were consistently higher with eptinezumab than placebo and increased following a second infusion. Conclusion In all subgroups, regardless of prior preventive treatment failure type, eptinezumab demonstrated greater reductions in MMDs and higher MRRs compared with placebo., Introduction: In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2–4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across the 24-week placebo-controlled period of the DELIVER study in subgroups defined by prior treatment failure type. Methods: DELIVER (NCT04418765) randomized adults with migraine to eptinezumab 100 mg, 300 mg, or placebo, administered intravenously every 12 weeks. Changes from baseline in MMDs and percentages of patients with ≥ 50% reduction from baseline in MMDs (≥ 50% migraine responder rates [MRRs]) were summarized in subgroups of patients defined by prior treatment failure type. Subgroups were not mutually exclusive and included patients for whom topiramate, beta blockers (metoprolol, propranolol), amitriptyline, and/or flunarizine had failed. Results: Across Weeks 1–12 in all subgroups, patients treated with eptinezumab experienced greater reductions from baseline in MMDs than those receiving placebo (reductions ranged from 4.5–5.5 vs 1.6–2.4, respectively), with larger reductions over Weeks 13–24. Similarly, ≥ 50% MRRs were consistently higher with eptinezumab than placebo and increased following a second infusion. Conclusion: In all subgroups, regardless of prior preventive treatment failure type, eptinezumab demonstrated greater reductions in MMDs and higher MRRs compared with placebo. Trial Registration: ClinicalTrials.gov (Identifier: NCT04418765).

Published
2024

32. The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group.

Author

Schwedt, Todd J., Pradhan, Amynah A., Oshinsky, Michael L., Brin, Mitchell F., Rosen, Howard, Lalvani, Nim, Charles, Andrew, Ashina, Messoud, Do, Thien Phu, Burstein, Rami, Gelfand, Amy A., Dodick, David W., Pozo‐Rosich, Patricia, Lipton, Richard B., Ailani, Jessica, Szperka, Christina L., Charleston, Larry, Digre, Kathleen B., Russo, Andrew F., and Buse, Dawn C.

Subjects
HEADACHE diagnosis, HEADACHE treatment, BIOLOGICAL models, RESEARCH funding, HEADACHE, RESEARCH evaluation, MEDICAL research, PRIORITY (Philosophy), PROFESSIONAL employee training, STAKEHOLDER analysis, PHYSICIANS, HEALTH equity, COMMITTEES, LABOR supply, EVALUATION
Abstract

Objective: To identify and disseminate research priorities for the headache field that should be areas of research focus during the next 10 years. Background: Establishing research priorities helps focus and synergize the work of headache investigators, allowing them to reach the most important research goals more efficiently and completely. Methods: The Headache Research Priorities organizing and executive committees and working group chairs led a multistakeholder and international group of experts to develop headache research priorities. The research priorities were developed and reviewed by clinicians, scientists, people with headache, representatives from headache organizations, health‐care industry representatives, and the public. Priorities were revised and finalized after receiving feedback from members of the research priorities working groups and after a public comment period. Results: Twenty‐five research priorities across eight categories were identified: human models, animal models, pathophysiology, diagnosis and management, treatment, inequities and disparities, research workforce development, and quality of life. The priorities address research models and methods, development and optimization of outcome measures and endpoints, pain and non‐pain symptoms of primary and secondary headaches, investigations into mechanisms underlying headache attacks and chronification of headache disorders, treatment optimization, research workforce recruitment, development, expansion, and support, and inequities and disparities in the headache field. The priorities are focused enough that they help to guide headache research and broad enough that they are widely applicable to multiple headache types and various research methods. Conclusions: These research priorities serve as guidance for headache investigators when planning their research studies and as benchmarks by which the headache field can measure its progress over time. These priorities will need updating as research goals are met and new priorities arise. Plain Language Summary: The American Headache Society led a large, international, multistakeholder process to identify headache research topics that should be prioritized during the next 10 years. With input from headache clinicians, scientists, people with headache, representatives from headache organizations, health‐care industry representatives, and the public, 25 research priorities within 8 categories were identified. These research priorities can help guide headache researchers when planning their studies and as benchmarks by which the headache field can measure its progress over time. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients

Author

Ornello, Raffaele, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Baraldi, Carlo, Guerzoni, Simona, Andreou, Anna P., Lambru, Giorgio, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzyński, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, and Sacco, Simona

Published
2021
Full Text
View/download PDF

37. Headaches and facial pain attributed to SARS‐CoV‐2 infection and vaccination: a systematic review

Author

Mitsikostas, Dimos‐Dimtirios D., primary, Caronna, Edoardo, additional, De Tommaso, Marina, additional, Deligianni, Christina I., additional, Ekizoglu, Esme, additional, Bolay, Hayrunnisa, additional, Göbel, Carl H., additional, Kristoffersen, Espen Saxhaug, additional, Lampl, Christian, additional, Moro, Elena, additional, Pozo‐Rosich, Patricia, additional, Sellner, Johann, additional, Terwindt, Gisela, additional, and Sieira, Pablo Irimia, additional

Published
2024
Full Text
View/download PDF

42. Diagnosis and management of migraine in ten steps

Author

Eigenbrodt, Anna K., Ashina, Håkan, Khan, Sabrina, Diener, Hans-Christoph, Mitsikostas, Dimos D., Sinclair, Alexandra J., Pozo-Rosich, Patricia, Martelletti, Paolo, Ducros, Anne, Lantéri-Minet, Michel, Braschinsky, Mark, del Rio, Margarita Sanchez, Daniel, Oved, Özge, Aynur, Mammadbayli, Ayten, Arons, Mihails, Skorobogatykh, Kirill, Romanenko, Vladimir, Terwindt, Gisela M., Paemeleire, Koen, Sacco, Simona, Reuter, Uwe, Lampl, Christian, Schytz, Henrik W., Katsarava, Zaza, Steiner, Timothy J., and Ashina, Messoud

Published
2021
Full Text
View/download PDF

44. Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study

Author

Ornello, Raffaele, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Baraldi, Carlo, Guerzoni, Simona, Andreou, Anna P., Lambru, Giorgio, Frattale, Ilaria, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzynski, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, and Sacco, Simona

Published
2021
Full Text
View/download PDF

45. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Author

Mulleners, Wim M, Kim, Byung-Kun, Láinez, Miguel J A, Lanteri-Minet, Michel, Pozo-Rosich, Patricia, Wang, Shufang, Tockhorn-Heidenreich, Antje, Aurora, Sheena K, Nichols, Russell M, Yunes-Medina, Laura, and Detke, Holland C

Published
2020
Full Text
View/download PDF

47. Design of the contemporary prospective understanding of migraine real-world evidence (CAPTURE) study

Author

Lanteri-Minet, Michel, primary, Tassorelli, Cristina, additional, Ashina, Messoud, additional, Goadsby, Peter, additional, Katsarava, Zaza, additional, Matharu, Manjit, additional, Peres, Mario, additional, Stark, Richard, additional, Ailani, Jessica, additional, Leroux, Elizabeth, additional, Delahaye, Laurent, additional, Ha, Huy, additional, and Pozo-Rosich, Patricia, additional

Published
2023
Full Text
View/download PDF

48. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study

Author

Ashina, Messoud, primary, Mitsikostas, Dimos D., additional, Amin, Faisal Mohammad, additional, Kokturk, Pinar, additional, Schankin, Christoph J., additional, Sahin, Gurdal, additional, Pozo-Rosich, Patricia, additional, Dorman, Paul J., additional, Nežádal, Tomáš, additional, Poole, Anne Christine, additional, Martins, Isabel Pavão, additional, Sumelahti, Marja-Liisa, additional, Ramirez Campos, Verena, additional, Ahn, Andrew H., additional, Lyras, Leonidas, additional, and Tassorelli, Cristina, additional

Published
2023
Full Text
View/download PDF

50. Tension-type headache

Author

Ashina, Sait, Mitsikostas, Dimos D., Lee, Mi Ji, Yamani, Nooshin, Wang, Shuu-Jiun, Messina, Roberta, Ashina, Håkan, Buse, Dawn C., Pozo-Rosich, Patricia, Jensen, Rigmor H., Diener, Hans-Christoph, and Lipton, Richard B.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results